Insider trade

CEO exercised or converted 173K REGN derivative securities

Traded Dec 9, 2025 · Filed Dec 11, 2025

Regeneron PharmaceuticalsREGN

173K
Derivative units

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Dec 9, 2025
Reporting period: Not applicable
Filed with the SEC: Dec 11, 2025

CEOOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001218629-25-000006

Filed / recorded

Dec 11, 2025, 9:23 PM UTC

Added to OQRO

Oct 2, 2026, 12:28 PM UTC

Parser

form4-xml-v1

Data quality

Verified: identifiers matched exactly

Issuer

REGENERON PHARMACEUTICALS, INC.

Issuer CIK

872589

Ticker

REGN

Reporting person

Leonard S Schleifer

Relationship

Director, Officer

Officer title

Bd. Co-Chair, President & CEO

Security

Non-Qualified Stock Option (right to buy)

Table

Derivative (Table II)

Transaction date

Dec 9, 2025

Transaction code

M

Shares / units

172,723

Price per share

$0.00

Acquired / disposed

Disposed (D)

Shares owned after

0

Ownership form

Direct

Amendment

No

Footnotes from the filing

The stock option award vested in four equal annual installments, commencing one year after the date of grant.

Around the same time

1,500Shares · @ $374.12

9mo ago

Derivative exercise or conversion — not an open-market buy.

More Official record

Director sold ~$1.2M of Regeneron Pharmaceuticals

Scheduled in advance9mo ago

1,500Derivative units

9mo ago

Derivative exercise or conversion — not an open-market buy.

More Official record